Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Research and Innovation Action · Running

END-VOC Ending Covid 19 Variants of Concern Through Cohort Studies: End-voc

Coordinator
University College London, United Kingdom
Runs
1 May 2022 to 31 October 2025
Status
Running
EU funding
€10.5m
Total cost
€10.5m
Partners
25 organisations in 18 countries
Type
Research and Innovation Action
Grant agreement
101046314

What the project is doing

In the project's own words, from its summary on CORDIS.

The END-VOC consortium will support the European and global response to the COVID-19 pandemic and Variants of Concern (VOC) through well characterised cohorts and linked with existing European and international initiatives. END-VOC consists of 19 partners in Europe (UK, Spain, Italy, Germany, Netherlands, Norway, Italy), South America (Brazil and Peru), Africa (Mozambique, South Africa, Nigeria and 13 ANTICOV African countries), Middle East (Palestine) and Asia (India, Pakistan, Philippines) with a focus on countries affected by VOCs and VOIs.

We will elucidate the global circulation of the current and emerging SARS-CoV-2 VOCs and their characteristics, including transmissibility, pathogenicity and propensity to cause reinfection, to support best control strategies and the development of diagnostics; evaluate the impact of VOCs on the effectiveness of different vaccines and vaccination strategies; and assess the implications of VOCs on the choice of optimal treatment options.

END-VOC will also investigate how VOCs alter long-term post-infection sequelae and where new VOCs emerge within hosts using our clinical cohorts. We will inform future preparedness and response working closely with international and national public health organisations and existing cohort consortia. Specific beyond state-of-the-art components of END-VOC include the use of novel phylogenetic prediction tools and mathematical modelling; generation of powerful cohorts through sentinel surveillance in low and middle income settings and cohorts of travellers to increase our global reach; use of novel predictive modelling of clinical outcomes by VOC and comorbidity/treatment and evaluation of differences in natural and vaccine immunity by VOC; antiviral screening models within cohorts and an artificial intelligence driven tool for the prediction of long COVID.

Topics

Who is involved

OrganisationCityCountryRole
University College LondonLondonUnited KingdomCoordinator
Fiotec-Fundacao Para O Desenvolvimento Cientifico E Tecnologico Em SaudeRio De JaneiroBrazilThird party
Fundacao Oswaldo CruzRio De JaneiroBrazilParticipant
Drugs for Neglected Diseases Initiative FondationGeneveSwitzerlandParticipant
Universite De GeneveGeneveSwitzerlandParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
Fundacio Institut Universitari Pera La Recerca a L'atencio Primaria De Salut Jordi Gol I GurinaBarcelonaSpainParticipant
Fundacion Privada Instituto De Salud Global BarcelonaBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Institut Catala De La SalutBarcelonaSpainThird party
Institut De Investigacio En Ciencies De La Salut Germans Trias I PujolBadalona BarcelonaSpainParticipant
Public Health Foundation of IndiaNew DelhiIndiaParticipant
Fondazione Irccs Ca' Granda - Ospedale Maggiore PoliclinicoMilanoItalyParticipant
Universita Degli Studi Di MilanoMilanoItalyParticipant
Laboratoire National De SanteDudelangeLuxembourgParticipant
Fundacao ManhicaVila Da Manhica MaputoMZParticipant
Nigeria Centre for Disease Control and PreventionAbujaNGParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
FolkehelseinstituttetOsloNorwayParticipant
University of the Philippines SystemQuezon CityPHParticipant
Dopasi FoundationIslamabadPKParticipant
Arab American UniversityJeninPSParticipant
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
African Field Epidemiology Network LbgKampalaUGThird party
University of WashingtonSeattle WaUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI